Viral Warts
Conditions
Interventions
Control group 1:Single heat therapy
Control group 2:Heat therapy combined with microneedle patch group (containing 9% saline)
Experimental group:Heat therapy combined with hydrogen peroxide (H?O?) microneedle patch group
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age: 6-65 years, no gender restriction; 2. Clinically diagnosed with common warts or palmar/plantar (toe) warts (number of lesions >=1), Physician's Wart Assessment score >=2 (0 points: no visible warts, no further treatment required; 1 point: visible warts, diameter less than 3mm; 2 points: single wart with diameter >=3mm and =6mm); 3. Subjects or legal guardians able to understand and sign the informed consent form/agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Subjects with clinically atypical warts; 2. Subjects with immune dysfunction or autoimmune diseases; 3. Pregnant or breastfeeding women; 4. Subjects who have received human papillomavirus (HPV) vaccination within the past 6 months; 5. Subjects who have undergone the following systemic treatments within a certain period: immunomodulators/immunosuppressants (such as etanercept) within 4 months; glucocorticoids (inhaled or intranasal use allowed) within 1 month; 6. Subjects who have received the following treatments on the warts or around the warts within a certain period: laser or other photochemical therapy (intense pulsed light, photodynamic therapy) within 3 months; immunotherapy (candida antigen) within 4 months; liquid nitrogen within 2 months; hydrogen peroxide within 3 months; antimetabolic drug treatment (5-fluorouracil) within 2 months; vitamin A derivatives within 3 months; 7. Subjects who have previously had the following conditions before visiting: malignant skin tumors, precancerous skin lesions (actinic keratosis) within the past 6 months, or currently have an acute progression of skin or systemic diseases (such as psoriasis, atopic dermatitis, eczema, sun damage, etc.) or symptoms (such as sunburn, open wounds) that may increase risks from participating in the study or assessments; 8. Subjects with diseases affecting skin healing, such as diabetes or vitamin A deficiency; 9. Subjects with coexisting conditions like cryoglobulinemia, cold urticaria, or other cold sensitivity that may cause abnormal observations; 10. Subjects with severe dysfunction of the heart, lungs, liver, kidneys, or hematopoietic system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical and dermoscopic cure rates of subjects in the three treatment groups;Rate of change in clinical scores and dermoscopy scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of first rash peeling;Rate of change in target lesion area;VAS score, NRS-11 score change rate;Virus clearance rate;The impact of different virus types and genetic backgrounds on treatment response; | — |
Countries
China
Contacts
Public ContactHao Guo
The First Hospital of China Medical University
Outcome results
None listed